

# Test Catalog

Diagnostic. Prognostic. Predictive. Predisposition.





# KIT (c-KIT) Mutation Analysis

#### **Alternative Name**

c-KIT Mutation Analysis

### Methodology

Molecular

# **Test Description**

Bi-directional sequencing of KIT exons 8, 9, 11, 13 and 17 for detection of activating mutations including the common mutation D816V. For solid tumors, tumor enrichment is performed before extraction. In hematological disease, testing may be performed on plasma to increase sensitivity. Testing is approved for specimens from the state of New York.

## **Clinical Significance**

The four tested exons encompass the majority of mutations found in gastrointestinal stromal tumors (GIST), melanoma, corebinding factor AML (CBF-AML), mast cell disease (systemic mastocytosis), and germ cell tumors. Mutation identification is useful for planning TKI therapy and predicting clinical course.

# **Specimen Requirements**

- Peripheral blood: 5 mL in EDTA tube.
- Bone marrow: 2 mL in EDTA tube.
- Fixed cytogenetic cell pellet: Send all available cells suspended in fixative.
- **FFPE solid tumor tissue:** Paraffin block is preferred. Alternatively, send 1 H&E slide plus 5-10 unstained slides cut at 5 or more microns. Please use positively-charged slides and 10% NBF fixative. Do not use zinc fixatives.

Note: Test in DNA-based, suitable for Freeze & Hold option.

#### **Storage & Transportation**

Use cold pack for transport, making sure cold pack is not in direct contact with specimen. Slides can be packed at room temperature.

# CPT Code(s)\*

81272

#### **New York Approved**

Yes

#### **Level of Service**

Global

#### **Turnaround Time**

7 days

Please direct any questions regarding coding to the payor being billed.

<sup>\*</sup>The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party.

NeoGenomics Laboratories is a specialized oncology reference laboratory providing the latest technologies, testing partnership opportunities, and interactive education to the oncology and pathology communities. We offer the complete spectrum of diagnostic services in molecular testing, FISH, cytogenetics, flow cytometry, and immunohistochemistry through our nation-wide network of CAP-accredited, CLIA-certified laboratories.

Committed to research as the means to improve patient care, we provide Pharma Services for pharmaceutical companies, in vitro diagnostic manufacturers, and academic scientist-clinicians. We promote joint publications with our client physicians. NeoGenomics welcomes your inquiries for collaborations. Please contact us for more information.

\*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party.

Please direct any questions regarding coding to the payor being billed.



9490 NeoGenomics Way Fort Myers, FL 33912

Phone: 239.768.0600/ Fax: 239.690.4237

neogenomics.com

Rev. 050524